2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Hall B
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Study Population, Animal Model
PAPER

362 Mitochondrial ferroptosis activates endogenous viral mimicry and enhances antileukemia immunity in acute myeloid leukemia

Saurabh Kumar Kumar Gupta, Postdoctoral Fellow, Marcela Gronda2, Ran Zhao, MSc3, Liang Zhang, PhD4, Kazuharu Kamachi5, Hiroki Akiyama6, Li Li, MD, PhD7, Silvia Tiberti8, Babita Kaundal9, Byron Jia10, Lauren Ostermann11, Taylor Barbieri12, Rose Hurren13, Geethu Emily Thomas, PhD, MSc, BSc14, Yu-Hsuan Chang, PhD15, Susumu Goyama, MD, PhD16, Hussein Ali Abbas, MD, PhD17, Ziyi N/A Li18, Branko Cuglievan, MD19, Yuki Nishida, MD, PhD20, Guillermo Garcia-Manero, MD21, Bing Z Carter, PhD22, Katayoun Rezvani, MD, PhD23, May Daher, MD, MD24, Michael Andreeff, MD, PhD25, Aaron Schimmer, MD PhD26, Jo Ishizawa, MD, PhD27
1 MD Anderson Cancer Center, Houston, Texas, United States
2 Princess Margaret Cancer Centre, University Health Network,, Toronto, Canada
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 Division of Hematology, Saga University, Saga, Japan
6 Department of Hematology, Institute of Science Tokyo, Tokyo, Japan
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 Princess Margaret Cancer Centre, University Health Network,, Toronto, Canada
13 Princess Margaret Cancer Centre, University Health Network,, Toronto, Canada
14 Princess Margaret Cancer Centre, University Health Network,, Toronto, Canada
15 Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
16 Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
17 MD Anderson Cancer Center, Houston, Texas, United States
18 MD Anderson Cancer Center, Houston, Texas, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 MD Anderson Cancer Center, Houston, Texas, United States
21 MD Anderson Cancer Center, Houston, Texas, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 MD Anderson Cancer Center, Houston, Texas, United States
24 MD Anderson Cancer Center, Houston, Texas, United States
25 MD Anderson Cancer Center, Houston, Texas, United States
26 Princess Margaret Cancer Centre, University Health Network,, Toronto, Canada
27 MD Anderson Cancer Center, Houston, Texas, United States

Resistance and relapse following apoptosis-based therapies, including with the BCL2 inhibitor venetoclax (VEN), and poor responses to cellular immunotherapies remain major clinical challenges in acute myeloid leukemia (AML). Therefore, strategies that overcome apoptosis resistance and induce durable antileukemia immunity remain unmet clinical needs. Ferroptosis, a form of iron-dependent lipid peroxidation-driven regulated cell death controlled by glutathione peroxidase 4 (GPX4), represents a promising alternative therapeutic modality. We recently demonstrated that GPX4 inhibition induces a distinct mitochondria-dependent ferroptosis in AML, termed “mitochondrial ferroptosis,” highlighting the new therapeutic potential (Leukemia (2024) 38:729-740). However, its effect on AML immunity remains unexplored.

Unbiased pathway enrichment analysis of RNA-seq data from AML cells treated with the selective GPX4 inhibitor ML210 revealed activation of interferon signaling, including the hallmark of interferon-γ response and inflammation, together with RIG-I-like receptor signaling, a major cytosolic RNA-sensing pathway, and cytosolic DNA-sensing pathways, suggesting the activation of innate immune signaling. Quantitative RT-PCR confirmed induction of interferon response genes, including IFN-γ (p<0.05), IFN-β (p<0.001), IFNGR1 (p<0.05), and ISG15 (p<0.05) after GPX4 inhibition in AML cells. These findings led us to hypothesize that mitochondrial ferroptosis activates mitochondrial nucleic acid-sensing pathways to enhance antileukemia immunity.

Indeed, confocal microscopy demonstrated significant accumulation of mitochondrial and cytosolic double-stranded RNA (dsRNA) and double-stranded DNA (dsDNA) following GPX4 inhibition by ML210 treatment (p<0.0001). Furthermore, pharmacological inhibition of TBK1 with GSK8612, the common downstream kinase of the MAVS/RIG-I and cGAS-STING pathways, attenuated the induction of interferon-response genes, supporting activation of endogenous viral mimicry during mitochondrial ferroptosis.

 We next investigated the functional consequences of ferroptosis-induced viral mimicry on antileukemia immunity. AML cells were primed for ferroptosis by either genetic GPX4 knockdown (GPX4-KD) or pharmacological inhibition with RSL3 (another established GPX4 inhibitor) or ML210, followed by co-culture with NK-92 cells, IL-15-NK cells, or CD123-CAR-T cells. Immune-mediated AML cell killing was quantified using time-lapse live-cell imaging (IncuCyte). Ferroptosis-primed AML cells were markedly more susceptible to immune-mediated cytotoxicity than control AML cells (p<0.0001). In addition, co-culture with ferroptosis-primed AML cells significantly increased expression of the activation markers NKp46 (p<0.001) and CD69 (p<0.01) on NK and T cells, respectively, indicating enhanced immune activation.

To determine whether this strategy applies to clinically challenging AML, we evaluated VEN-resistant (VEN-R) and TP53-mutant (Y220C and R273H) AML cell line models. Similar to treatment-naïve AML, ferroptosis induction significantly sensitized these VEN-R and TP53-mutant AML cells to NK- and CD123-CAR-T-cell-mediated killing (p<0.0001), demonstrating its potential to overcome therapy resistance and restore immune susceptibility. Furthermore, we found that GPX4 inhibition significantly upregulated surface CD70 expression on AML cells (p<0.05). Consequently, GPX4-KD or RSL3-treated treatment-naïve, VEN-R, and TP53-mutant AML cells exhibited significantly enhanced susceptibility to CD70-CAR-NK-cell-mediated cytotoxicity (p<0.001).

Finally, these findings were validated in vivo using a luciferase-labeled, doxycycline-inducible GPX4-knockdown (GPX4-KD) MOLM13 xenograft model. GPX4-KD combined with IL-15-NK, CD70-CAR-NK, or CD123-CAR-T cells significantly reduced leukemia burden (>10-fold; p<0.001) and extended median survival by ~50%, ~40%, and ~55%, respectively, compared with either GPX4-KD or cellular therapy alone (p<0.0001).

Collectively, these findings indicate that mitochondrial ferroptosis induces accumulation of dsRNA and dsDNA, activating MAVS- and cGAS-STING-dependent innate immune signaling and type I interferon responses through endogenous viral mimicry. The immune reprogramming in ferroptosis-primed AML cells enhances NK-, CAR-NK-, and CAR-T-cell-mediated cell killing, providing a promising strategy to overcome therapy resistance while improving the efficacy of cellular immunotherapy.

Saurabh Kumar Kumar Gupta, Postdoctoral Fellow: No relevant conflicts of interest to declare.